IRB Approval - Abt

Institutional Review Board Notice of Approval
Principal Investigator/Project Director:
Project Title:

CDC Opioid Guideline Evaluation

Sponsor Agency:
Abt IRB #:

Ellen Childs

GDIT

2265

Protocol Approval Date:

May 24, 2024

Review Type:

Expedited

Type of Approval:

Full Implementation

Please note the following requirements:
Problems or adverse reactions: If any problems in treatment of human subjects or unexpected
adverse reactions occur as a result of this study, you must notify the IRB Chairperson or IRB
Administrator immediately.
Consent forms: In the event the approved study includes procedures for written informed
consent, you only may use consent forms that bear the Abt Associates Inc. (or lead/local) IRB
approval stamp.
Changes in protocol, study design, or study materials: If there are changes in procedures,
the study design, or study materials (e.g., survey instruments, consent forms), you must submit
these materials for IRB review and approval before they are implemented.
Renewal: You are required to apply for renewal of approval at least annually for as long as the
study is active. Your next review date should be on or before Exempt
.
Teresa Doksum, Ph.D., M.P.H.
IRB Chair
Abt Associates Inc.
10 Fawcett Street, Suite 5
Cambridge, MA 02138
[email protected]
617-349-2896
Cc:

Date: May 24, 2024